<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04536636</url>
  </required_header>
  <id_info>
    <org_study_id>DHA-HD (188-16)</org_study_id>
    <nct_id>NCT04536636</nct_id>
  </id_info>
  <brief_title>Docohexanoic Acid in Hemodialysis Patients</brief_title>
  <official_title>Effect of Oral Administration of Docohexanoic Acid on Anemia-inflammation in Hemodialysis Patients. A Randomized Clinical Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Fundacion para la Investigacion Biomedica del Hospital Universitario Ramon y Cajal</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Fundacion para la Investigacion Biomedica del Hospital Universitario Ramon y Cajal</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Docohexanoic acid (DHA), a dietary n-3 polyunsaturated fatty-acid omega-3 (n-3, PUFA), showed&#xD;
      potential beneficial effects in reducing all-cause mortality in hemodialysis (HD) patients.&#xD;
      This clinical trial aimed to analyze whether DHA supplementation was a modulator of&#xD;
      erythropoietin (EPO) response and inflammation in hemodialysis (HD) patients.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Background. Docohexanoic acid (DHA), a dietary n-3 polyunsaturated fatty-acid omega-3 (n-3,&#xD;
      PUFA), showed potential beneficial effects in reducing all-cause mortality in hemodialysis&#xD;
      (HD) patients. This clinical trial aimed to analyze whether DHA supplementation was a&#xD;
      modulator of erythropoietin (EPO) response and inflammation in hemodialysis (HD) patients.&#xD;
&#xD;
      Methods. In single-blind, controlled clinical trial, 52 HD patients were randomized to either&#xD;
      DHA supplementation (650 mg DHA/3 times/wk/post-HD session) or controls (usual medical-care)&#xD;
      for 8-weeks. Clinical data by collecting hemoglobin concentration (Hb), weekly dose of EPO,&#xD;
      and erythropoietin resistance index (ERI). The inflammatory response was measured using serum&#xD;
      C-reactive protein (s-CRP) and plasma homocysteine (tHcy) at baseline (T0) and&#xD;
      post-intervention (T1). miR-146a array was used as an inflammatory biomarker.&#xD;
      Post-intervention measures were analyzed at 4-weeks intervals and adjusted by baseline in a&#xD;
      linear regression.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">June 1, 2018</start_date>
  <completion_date type="Actual">September 30, 2018</completion_date>
  <primary_completion_date type="Actual">September 30, 2018</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Determine correction of anemia</measure>
    <time_frame>Determine correction of anemia measured by erythropoiesis-resistance index (ERI) to detect a difference of 10 units of response between groups at 8 weeks follow-up, with a SD of 10 and a power higher than 80%.</time_frame>
    <description>Determine correction of anemia measured by erythropoiesis-resistance index (ERI) to detect a difference of 10 units of response between groups at 8 weeks follow-up, with a SD of 10 and a power higher than 80%.</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">42</enrollment>
  <condition>Chronic Renal Failure</condition>
  <arm_group>
    <arm_group_label>Control</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>The patients on this arm received usual medical care</description>
  </arm_group>
  <arm_group>
    <arm_group_label>DHA supplementation</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>The patients on this arm received DHA supplementation (650 mg DHA/3 times/wk/post-HD session)</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Docohexanoic acid</intervention_name>
    <description>Patients received 650 mg DHA/3 times/wk/post-HD session</description>
    <arm_group_label>DHA supplementation</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Control-No drug</intervention_name>
    <description>Patients received usual medical care with no DHA</description>
    <arm_group_label>Control</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  age over 18 years&#xD;
&#xD;
          -  chronic stabilized HD treatment for at least 3 months with functional vascular access&#xD;
             (arteriovenous fistula or permanent catheter)&#xD;
&#xD;
          -  equilibrated Kt/V urea (eKt/V)higher than 1.2&#xD;
&#xD;
          -  informed consent form signed&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  exposure to corticosteroids and anti-inflammatory drugs or hospital admissions in last&#xD;
             3 months&#xD;
&#xD;
          -  were with ongoing active illnesses, wasting, connective tissue disease, metastatic&#xD;
             cancer or malignancy, HIV, uncontrolled chronic hepatic disease or transplantation&#xD;
             prior to the start of the study.&#xD;
&#xD;
          -  Patients with known hypersensitivity to any of fish intolerance or allergy, history of&#xD;
             gastrointestinal bleeding, patients already receiving chronic anticoagulation therapy&#xD;
             (antiplatelet agents or warfarin), and patients with terminal or life-threatening&#xD;
             disease.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Hospital Ram√≥n y Cajal</name>
      <address>
        <city>Madrid</city>
        <zip>28034</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Spain</country>
  </location_countries>
  <verification_date>August 2020</verification_date>
  <study_first_submitted>August 25, 2020</study_first_submitted>
  <study_first_submitted_qc>August 28, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">September 2, 2020</study_first_posted>
  <last_update_submitted>September 16, 2020</last_update_submitted>
  <last_update_submitted_qc>September 16, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">September 17, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Kidney Failure, Chronic</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

